Geron Corporation Total Assets 2011-2026 | GERN

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Geron Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
571 M	594 M	394 M	191 M	226 M	271 M	166 M	185 M	110 M	130 M	149 M	173 M	67.3 M	99.8 M	160 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
594 M	67.3 M	232 M

Quarterly Total Assets Geron Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
567 M	555 M	562 M	445 M	449 M	482 M	413 M	415 M	425 M	191 M	233 M	238 M	198 M	226 M	229 M	252 M	259 M	271 M	271 M	271 M	271 M	166 M	166 M	166 M	166 M	185 M	185 M	185 M	185 M	110 M	110 M	110 M	110 M	130 M	130 M	130 M	130 M	149 M	149 M	149 M	149 M	173 M	173 M	173 M	173 M	67.3 M	67.3 M	67.3 M	67.3 M	99.8 M	99.8 M	99.8 M	99.8 M	160 M	160 M	160 M	160 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
567 M	67.3 M	214 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
Amphastar Pharmaceuticals AMPH	1.63 B	$ 21.65	1.12 %	$ 1.01 B	USA
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	54.8 M	-	-	$ 8.42 M	USA
Aptorum Group Limited APM	18.7 M	$ 0.9	-0.18 %	$ 6.62 M	China
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	1.19 B	$ 22.3	1.55 %	$ 3.7 B	USA
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Brainstorm Cell Therapeutics BCLI	1.02 M	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	325 M	-	-4.8 %	$ 255 M	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Cara Therapeutics CARA	32.1 M	-	-3.03 %	$ 260 M	USA
CASI Pharmaceuticals CASI	138 M	-	-	$ 35.4 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
ChromaDex Corporation CDXC	106 M	-	-0.88 %	$ 598 M	USA
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	14.7 M	-	17.91 %	$ 11.1 M	USA
BioNTech SE BNTX	22 B	$ 102.06	-3.22 %	$ 27.2 B	Germany
Checkpoint Therapeutics CKPT	7.47 M	-	-	$ 169 M	USA
Avenue Therapeutics ATXI	2.93 M	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	160 M	$ 4.1	0.49 %	$ 438 M	USA
Arcutis Biotherapeutics ARQT	433 M	$ 23.42	0.69 %	$ 2.98 B	USA
Autolus Therapeutics plc AUTL	589 M	$ 1.42	-1.39 %	$ 378 M	Britain
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
AVROBIO AVRO	101 M	-	1083.1 %	$ 745 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 2.92	-0.34 %	$ 4.81 M	Israel
BeiGene, Ltd. BGNE	8.19 B	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
bluebird bio BLUE	619 M	-	-	$ 546 M	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
ContraFect Corporation CFRX	20.7 M	-	-5.16 %	$ 5.39 M	USA
Cardiff Oncology CRDF	61.9 M	$ 1.72	-	$ 115 M	USA
CTI BioPharma Corp. CTIC	126 M	-	-	$ 1.2 B	USA
BioXcel Therapeutics BTAI	44.9 M	$ 1.09	2.83 %	$ 13.3 M	USA